Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Zealand Pharma A/S (22Z.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
27.42+0.54 (+2.01%)
At close: 8:05AM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close26.88
Open27.42
Bid0.00 x 60000
Ask0.00 x 60000
Day's Range27.42 - 27.42
52 Week Range22.26 - 33.24
Volume154
Avg. Volume4
Market Cap1.192B
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-3.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Total number of shares and voting rights in Zealand Pharma at September 30, 2021

    Company announcement – No. 62 / 2021 Total number of shares and voting rights in Zealand Pharma at September 30, 2021 Copenhagen, DK and Boston, MA, September 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at

  • GlobeNewswire

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

    Company announcement – No. 61 / 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, DK and Boston, MA, U.S., September 10, 2021 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares

  • GlobeNewswire

    Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

    Company announcement – No. 60 / 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, U.S. September 10, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 30,748 divided into 30,748 new shares with a nominal value of DKK 1 each. The

Advertisement
Advertisement